Adalimumab, trade names Humira ("human monoclonal antibody in rheumatoid arthritis") and Exemptia are TNF inhibiting anti-inflammatory drug manufactured by AbbVie and Zydus Cadila respectively. Adalimumab binds to tumor necrosis factor-alpha (TNFα). TNFα normally binds to TNFα receptors, which leads to the inflammatory response of autoimmune diseases. By binding to TNFα, adalimumab reduces this inflammatory response.